Tadalafil is a once-a-day oral medication for the treatment of Pulmonary Arterial Hypertension (PAH). Adcirca is indicated to improve exercise ability in WHO Group I PAH patients, which encompasses patients with multiple forms of PAH including etiologies such as idiopathic and familial PAH as well as PAH associated with scleroderma and congenital heart disease. Tadalafil is also marketed under the drug name Cialis®. 

Adcirca is an oral medication in pill form.  The usual dosing is one (1) tablet (40mg) once each day.

Adcirca should not be used in patients taking medications that contain nitrates, as the combination could cause a sudden, unsafe drop in blood pressure. The most common side effects reported with Adcirca were headache, muscle pain, nasal swelling, flushing, respiratory tract infection, extremity pain nausea, back pain, upset stomach, and nasal congestion.

During trial, many side effects, including headache, nausea, back pain, dyspepsia, visual blurring, and chest pain seemed to have a dose-dependent effect, with the highest incidence in the 40 mg tadalafil arm. No changes were noted in mean systemic blood pressure.

• Once-daily dosing
• No requirement for monthly liver tests
• Lack of titration for some patients
• Ability to be taken with or without food
• Availability at both retail and specialty pharmacies

Adcirca will cost $8,000 to $9,000 per year, the same as daily Cialis.

Frequently Asked Questions by Patients about Adcirca®

Adcirca Financial Reimbursement Hotline

Eli Lilly and Company holds the exclusive rights to manufacture Adcirca (tadalafil) until May 2012. After these exclusivity rights expire, various other companies may manufacture a generic Adcirca product. However, lawsuits or other patents for specific uses of the drug may delay the manufacturing of a generic product.